Nyxoah SA (NYXH) Q4 2025 Earnings Call Highlights: U.S. Launch Success and Financial Challenges By GuruFocus

EUR 11.0m global gross revenue in 2025 following U.S. FDA approval and a U.S. launch, with $4.5m in revenue in Q4 2025 driven by initial implants and surgeon training. Operating loss widened to EUR 83.5m (from EUR 58.8m) and cash burn is ~EUR 20m/quarter with EUR 48m of cash at 12/31/2025, but management says recent PIPE and convertible debt fund operations into Q1 2027. Key near-term catalysts/risk factors include VAC approval timelines, new interim CMS C-codes, the ACCCESS 12-month data (due end-June) and PMA supplement targeting early 2027, plus competitive pressure from potential entrants like LivaNova.

Analysis

The product’s device-level advantages create a clear hospital ROI vector: anything that meaningfully shortens OR time and simplifies patient flow converts the “clinical interest” signal into booked cases faster than devices that require complex inventory or long training pipelines. That implies adoption will be highly concentrated in a subset of accounts that value throughput gains — expect a skewed rollout where top centers account for the majority of early volume, producing lumpy revenue and uneven operator learning curves.

A strategic inflection is the entrance (or credible threat) of large med‑tech competitors with incumbent hospital relationships. Those entrants will not only compete on price but can bundle adjacent capital equipment and service contracts, forcing smaller entrants to defend margin via higher services content or restricting channel access. Second‑order beneficiaries include distributors and OR consumable suppliers that enable faster case turnover; conversely, independent specialty sales shops that rely on single-product economics will see margin compression.

Balance‑sheet and coding friction create a binary outcome set over the next 6–24 months: either execution on commercial penetration and reimbursement streamlining materially derisks the story, or delayed coding/credentialing and competitive pressure force dilutive financings. This sets a trade environment that favors defined‑risk, event‑driven exposures around the next cluster of clinical and commercial inflection points rather than outright long‑only sized positions.

Given the path dependence, sizing should be tactical and time‑aware: prioritize instruments that limit theta and cap downside while preserving asymmetric upside to regulatory/commercial beats. Simultaneously monitor early account-level throughput metrics and hospital billing rejection rates as high‑signal, leading indicators of real adoption versus anecdotal surgeon interest.

Key Decisions for Investors

• Long NYXH via defined‑risk LEAP call spread (e.g., Jan‑2028 buy 25 / sell 45 calls) — initial size 1–2% NAV. Rationale: asymmetric upside to successful clinical/commercial beats while limiting premium decay; downside = premium (~100% loss of premium), upside = 2–4x on spread if catalysts materialize. Enter immediately, trim 30–50% on first large positive datapoint (clinical or billing uptake).
• Pair trade to fund risk: Buy NYXH equity (1% NAV) and short LIVN (0.5% NAV) to hedge general med‑tech beta. R/R: if NYXH re‑rates, equity gain outweighs modest short; if competitive entry accelerates, short offset cushions downside. Use 30% stop on the long and 40% stop on the short to control tail risk.
• Event hedge: Sell short‑dated NYXH calls (3–4 months) against the LEAP to finance cost if comfortable taking assignment risk — reduces net premium and monetizes calendar volatility ahead of near‑term commercial milestones. Only implement if position sizing caps max loss to <2% NAV.
• Risk-off trigger: If hospital billing rejection rates exceed 20% of submitted cases or a dilutive capital raise is announced, cut exposures by 50% and re-evaluate; probability of meaningful dilution given adverse execution >30%, so keep cash reserved for redeployment.